Lung Cancer
Volume 62, Issue 1 , Pages 78-84 , October 2008

High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy

  • Reury-Perng Perng

      Affiliations

    • Chest Department, Taipei Veterans General Hospital, School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Chih-Hsin Yang

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • These authors contributed equally to the present study.
    • ,
  • Yuh-Min Chen

      Affiliations

    • Chest Department, Taipei Veterans General Hospital, School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • These authors contributed equally to the present study.
    • Corresponding Author InformationCorresponding author at: Chest Department, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C. Tel.: +886 2 28763466; fax: +886 2 28763466.
    • ,
  • Gee-Chen Chang

      Affiliations

    • Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan
    • ,
  • Meng-Chih Lin

      Affiliations

    • Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaoshiung, Taiwan
    • ,
  • Ruey-Kuen Hsieh

      Affiliations

    • Department of Internal Medicine, Mackay Memorial Hospital, Taiwan
    • ,
  • Nei-Min Chu

      Affiliations

    • Department of Internal Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taiwan
    • ,
  • Ruay-Sheng Lai

      Affiliations

    • Department of Medicine, Kaohsiung Veterans General Hospital, Taiwan
    • ,
  • Wu-Chou Su

      Affiliations

    • Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan
    • ,
  • Chao-Jung Tsao

      Affiliations

    • Department of Internal Medicine, Chi-Mei Medical Center, Taiwan
    • ,
  • Te-Chun Hsia

      Affiliations

    • Department of Internal Medicine, China Medical University Hospital, Taiwan
    • ,
  • Hao-Cheng Chen

      Affiliations

    • Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan
    • ,
  • Chih-Hung Chen

      Affiliations

    • Department of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan
    • ,
  • Ming-Shyan Huang

      Affiliations

    • Department of Internal Medicine, Kaohsiung Medical University Hospital, Taiwan
    • ,
  • Jui-Long Wang

      Affiliations

    • Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaoshiung, Taiwan
    • ,
  • Ming-Lin Ho

      Affiliations

    • Department of Internal Medicine, Chunghua Christian Hospital, Taiwan
    • ,
  • Chih-Yuan Chung

      Affiliations

    • Department of Internal Medicine, Chunghua Christian Hospital, Taiwan
    • ,
  • Chong-Jen Yu

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Wen-Cheng Chang

      Affiliations

    • Department of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan
    • ,
  • Han-Pin Kuo

      Affiliations

    • Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan
    • ,
  • Chih-Teng Yu

      Affiliations

    • Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan
    • ,
  • Zhong-Zhe Lin

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Woei-Yau Kao

      Affiliations

    • Department of Internal Medicine, Tri-Service General Hospital, Taiwan

Received 8 January 2008 ,Revised 18 February 2008 ,Accepted 24 February 2008.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2005;55:74–108
  2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–353
  4. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354–2362
  5. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  7. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–1537
  8. Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, et al. Gefitinib (Iressa) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1:847–855
  9. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  11. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib (ZD1839) in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial (INTACT 1). J Clin Oncol. 2004;22:777–784
  12. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib (ZD1839) in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial (INTACT 2). J Clin Oncol. 2004;22:785–794
  13. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–5899
  14. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol. 2007;25:1545–1552
  15. Chen YM. Clinical application of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) against non-small cell lung cancer (NSCLC). J Cancer Mol. 2005;1:83–91
  16. Jänne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006;12(Suppl. 14):4416s–4420s
  17. Schneider C, Schott-von Römer K, Gütz S, Raack B, Dierkesmann R, Laack E, et al. Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2007;25:a7674
  18. García-Velasco A, Pérez-Carrión R, de Castro J, Garrido P, García R, González-Larriba JL, et al. Initial safety results of an open-label phase II trial of erlotinib in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol. 2007;25:a18038

PII: S0169-5002(08)00109-8

doi: 10.1016/j.lungcan.2008.02.023

Lung Cancer
Volume 62, Issue 1 , Pages 78-84 , October 2008

Article Tools

* Image Usage & Resolution